CRBU News

IPO activity continued at a record pace this past week with 19 IPOs, marking the fourth week in 2021 with at least 17 US IPOs, the most since the year 2000. With the August lull around the corner, the pipeline saw less activity than usual; five IPOs and 13 SPACs submitted initial filings. Protein therapy platform Absci (ABSI) priced at the midpoint to raise...read more

Caribou Biosciences, a Phase 1 biotech developing gene edited cell therapies for multiple cancers, raised $304 million by offering 19 million shares at $16, the high end of the range of $14 to $16. The company offered 2 million more shares than anticipated. It originally planned to offer 13.5 million shares at $14 to $16, before increasing the proposed share offering on Thursday. ...read more

Caribou Biosciences, a Phase 1 biotech developing gene edited cell therapies for multiple cancers, raised the proposed deal size for its upcoming IPO on Thursday. The Berkeley, CA-based company now plans to raise $255 million by offering 17 million shares at a price range of $14 to $16. The company had previously filed to offer 13.5 million shares at the same range. At the revised...read more

Caribou Biosciences, a Phase 1 biotech developing gene edited cell therapies for multiple cancers, announced terms for its IPO on Monday. The Berkeley, CA-based company plans to raise $203 million by offering 13.5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Caribou Biosciences would command a fully diluted market value of $827 million. ...read more